AZIN2 and cancer: Deprivation of circulating arginine via enzymes such as arginase, arginine deiminase (ADI), and arginine decarboxylase (ADC) exploits a significant metabolic vulnerability of cancer cells in these tumor types, and such enzyme-mediated arginine depletion is currently under clinical investigation along multiple fronts to advance this potential class of anticancer therapeutics (75–77).